fool.com · 30 jun

Director Sells 33,000 Impinj Shares Worth $4.6 Million

33,412 shares were sold indirectly on June 4, 2026, with an estimated transaction value of ~$4.57 million based on the reported price of $136.84 per share. This sale represented 3.63% of Sylebra Capital LLC's indirect holdings in Impinj, reducing total indirect ownership from 921,467 to 888,055 shares.

fool.com · 27 jun

Director Sells 45,000 Impinj Shares Worth $6.4 Million

45,037 shares were indirectly sold for a total transaction value of ~$6.4 million, based on a weighted average price of $141.87 per share during June 2–3, 2026. The sale represented 4.66% of Sylebra Capital LLC's indirect holdings, reducing indirect ownership from 967,000 to 921,467 shares; direct holdings remained at zero.

fool.com · 18 jun

Intel vs. Impinj: Which Technology Stock Is a Better Buy in 2026?

Intel is aggressively expanding its foundry business and AI accelerator offerings to diversify beyond traditional PC and data center chips. Impinj maintains a specialized lead in RAIN RFID technology, though its revenue remains highly concentrated among a small number of partners.

marketbeat.com · 17 jun

Insiders Are Selling These 3 Stocks—Should Investors Be Concerned?

Insider sales are hitting two massive stocks in industrials and retail, as well as a small-cap chip stock. Across these names, insiders are sending bearish signals, but their severity differs meaningfully.

gurufocus.com · 13 jun

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel

New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi

fool.com · 5 jun

Large Impinj Investor Trims Position by $11.3 Million

Impinj connects physical items to the digital world with advanced RFID solutions; a key insider recently reduced their indirect holdings.

gurufocus.com · 2 jun

Imagion Biosystems' IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

[url="]Imagion Biosystems, Ltd. (ASX: IBX)[/url] has announced that the US Food and Drug Administration (FDA) completed its review of the company's investigati

zacks.com · 27 may

Impinj (PI) Just Reclaimed the 200-Day Moving Average

After reaching an important support level, Impinj (PI) could be a good stock pick from a technical perspective. PI surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.